Effect of TCC Cocktail Combined With TACE Versus TACE Alone on Survival in uHCC Patients

Effect of Thalidomide, Carmofur and Compound Mylabris Capsules (TCC) Cocktail Combined With Transarterial Chemoembolization Versus Transarterial Chemoembolization Alone on Survival in Patients With Unresectable Hepatocellular Carcinoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07321613

Enrollment

545

Registered

2026-01-07

Start date

2023-05-01

Completion date

2025-06-01

Last updated

2026-01-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatocellular Cancer (HCC)

Brief summary

This is a multicenter, retrospective cohort study that aims to evaluate the efficacy and safety of a triple-drug cocktail (TCC), consisting of Thalidomide, Carmofur, and Compound Mylabris Capsules (CMC), in combination with conventional Transarterial Chemoembolization (TACE) for the treatment of patients with unresectable Hepatocellular Carcinoma (HCC).

Interventions

DRUGThalidomide (50mg)

Thalidomide tablets (Changzhou Pharmaceutical Factory, 50 mg qn)

DRUGcarmofur

carmofur tablets (Qilu Pharmaceutical, 100 mg, tid)

DRUGcompound mylabris capsule

CMC (Guizhou Yibai Pharmaceutical Co., Ltd, 750 mg, bid)

PROCEDURETACE

received initial treatment with traditional TACE by well-trained and experienced physicians

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients who met the HCC diagnostic criteria according to the Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China. * patients underwent conventional TACE. * availability of complete medical records for data extraction and follow-up.

Exclusion criteria

* a history of previous or synchronous treatment for tumors such as radio frequency ablation (RFA) or systemic chemotherapy. * poor liver functions (Child-Pugh class C). * accompanying other life-threatening diseases.

Design outcomes

Primary

Measure	Time frame	Description
Overall Survival (OS)	up to five years	Defined as the time interval from the date of the patient's first TACE treatment to the date of death from any cause or the date of the last follow-up (whichever occurred first).

Secondary

Measure	Time frame	Description
Objective Response Rate (ORR) at 6 Months	up to six months	The proportion of patients achieving a Complete Response (CR) or Partial Response (PR) according to mRECIST criteria at the 6-month follow-up after treatment initiation.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026